We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results:1-7 of 7

Federal Circuit Patent Updates - November 2017
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • November 8 2017

Moore, J. Reversing finding of nonobviousness and holding claims invalid as obvious. “The district court clearly erred in finding a skilled artisan


Follow-On Biologics': Ensuring Continued Innovation In The Biotechnology Industry
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • August 11 2016

The world of pharmaceuticals and patent law can be exceedingly complex. Or, to twist Gertrude Stein's words, it is not correct that a drug is a drug


Stay Versus Stay: How Litigation Stays Pending IPRs Impact the 30-Month Regulatory Stay in Hatch-Waxman Litigation
  • Wilmer Cutler Pickering Hale and Dorr LLP
  • USA
  • March 25 2016

Upon initiation of a patent infringement action between branded and generic pharmaceutical companies, the Hatch-Waxman Act (21 U.S.C. 355(j))


Andrea Weiss Jeffries
  • Wilmer Cutler Pickering Hale and Dorr LLP

Nancy L. Schroeder
  • Wilmer Cutler Pickering Hale and Dorr LLP

Bruce S. Manheim, Jr.
  • Wilmer Cutler Pickering Hale and Dorr LLP